Glioblastoma multiforme: a review of where we have been and where we are going
暂无分享,去创建一个
D. Bigner | A. Mattox | Darell D Bigner | O. Kanu | C. Di | N. Lin | Cory Adamson | Okezie O Kanu | Ankit I Mehta | Chunhui Di | Ningjing Lin | Austin K Mattox | Ankit I. Mehta | Cory Adamson
[1] M. Berger,et al. Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.
[2] K. Takakura,et al. Effects of ACNU and radiotherapy on malignant glioma. , 1986, Journal of neurosurgery.
[3] M. Berger,et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. , 2006, Neurosurgical focus.
[4] A. Unterberg,et al. Different angiogenic phenotypes in primary and secondary glioblastomas , 2006, International journal of cancer.
[5] P. Liberski,et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Marchioni,et al. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. , 2006, Anticancer research.
[7] R. McLendon,et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. , 1995, Oncogene.
[8] R. McLendon,et al. The glioblastoma multiforme in Georgia, 1977-1981. , 1985, Cancer.
[9] B. Scheithauer,et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Weller,et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[12] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[13] D. Pa,et al. Occupation, socioeconomic status, and brain tumor mortality: a death certificate-based case-control study. , 1991 .
[14] Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. , 1982, Neurosurgery.
[15] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[16] A. Merlo,et al. Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.
[17] D. Ledbetter,et al. Multicolor Spectral Karyotyping of Human Chromosomes , 1996, Science.
[18] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[19] M. Prados,et al. Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas. , 1990, Journal of neuro-oncology.
[20] T. Roszman,et al. Proliferative potential of T-cell lymphocytes from gliomas. , 1992, Journal of neurosurgery.
[21] F. Davis,et al. Epidemiology of brain tumors. , 2000, Current opinion in neurology.
[22] A. Poustka,et al. Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors , 2000, Journal of neuropathology and experimental neurology.
[23] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.
[24] W. Simpson,et al. Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial , 1982, Cancer.
[25] G. Duncan,et al. Pion radiation for high grade astrocytoma: results of a randomized study. , 1997, International journal of radiation oncology, biology, physics.
[26] D. Reardon,et al. Molecularly targeted therapy for malignant glioma , 2007, Cancer.
[27] L. Hodges,et al. Prevalence of Glioblastoma Multiforme in Subjects with Prior Therapeutic Radiation , 1992, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[28] Erwin G. Van Meir,et al. Quantitative real-time PCR does not show selective targeting of p14ARF but concomitant inactivation of both p16INK4A and p14ARF in 105 human primary gliomas , 2001, Oncogene.
[29] J. Costello,et al. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene , 1997, Molecular and cellular biology.
[30] Z. Ram,et al. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.
[31] T. Bouldin,et al. Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas. , 1987, Surgical neurology.
[32] J. Fraumeni,et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[33] D. Nelson,et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.
[34] N. Rainov. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.
[35] Ho-Keung Ng,et al. Detection of Multiple Gene Amplifications in Glioblastoma Multiforme Using Array-Based Comparative Genomic Hybridization , 2001, Laboratory Investigation.
[36] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[37] Veit Rohde,et al. EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS , 2008, Neurosurgery.
[38] H Kalimo,et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. , 1997, Neurosurgery.
[39] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[40] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[41] W. Cavenee,et al. EGFR gene amplification ‐ rearrangement in human glioblastomas , 1995, International journal of cancer.
[42] M. member. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. , 2001 .
[43] D P Byar,et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.
[44] C. Johansen,et al. Incidences of Gliomas and Meningiomas in Denmark, 1943 to 1997 , 2003, Neurosurgery.
[45] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.
[46] I. Parney,et al. Glioma immunology and immunotherapy. , 2000, Neurosurgery.
[47] N. Bleehen,et al. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.
[48] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[49] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[50] E. Alexander,et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. , 1989, International journal of radiation oncology, biology, physics.
[51] S. Green,et al. Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications , 1985, Cancer.
[52] A. Young,et al. Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. , 1981, Cancer treatment reports.
[53] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[54] D F Nelson,et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. , 1988, NCI monographs : a publication of the National Cancer Institute.
[55] B. Brownstein,et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.
[56] Caldwell Hd,et al. Immune responses in patients with gliomas. , 1974 .
[57] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[58] D. Long,et al. Outcome and Cost of Craniotomy Performed to Treat Tumors in Regional Academic Referral Centers , 2003, Neurosurgery.
[59] D. Thomas,et al. Impaired thymus-derived lymphocyte function in patients with malignant brain tumour , 1980, Clinical Neurology and Neurosurgery.
[60] M. Prados,et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. , 1996, Cancer research.
[61] E. Gehan,et al. Evaluation of mithramycin in the treatment of anaplastic gliomas. , 1976, Journal of neurosurgery.
[62] Kjell Hansson Mild,et al. Long-term use of cellular phones and brain tumours: increased risk associated with use for ⩾10 years , 2007, Occupational and Environmental Medicine.
[63] Eytan Domany,et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. , 2003, Cancer research.
[64] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[65] J. Olson,et al. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. , 1995, Cancer research.
[66] T. Roszman,et al. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. , 1977, Clinical and experimental immunology.
[67] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[68] J. Dixon,et al. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.
[69] A. Pawson,et al. Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.
[70] R Miike,et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. , 1997, American journal of epidemiology.
[71] Robert G. Selker,et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma , 2009 .
[72] J. Sotelo,et al. Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme , 2006, Annals of Internal Medicine.
[73] J. Olson,et al. The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine , 2002, Neurosurgery.
[74] E. Gehan,et al. Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study. , 1986, Cancer treatment reports.
[75] T. Roszman,et al. Impairment of rosette‐forming T lymphocytes in patients with primary intracranial tumors , 1976, Cancer.
[76] M. Prados,et al. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade , 1998, Genes, chromosomes & cancer.
[77] Gabriele Schackert,et al. Long-term survival with glioblastoma multiforme. , 2007, Brain : a journal of neurology.
[78] Y. Yonekawa,et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.
[79] Erwin G. Van Meir,et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.
[80] D. Áfra,et al. Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. , 1983, Journal of neurosurgery.
[81] P. Willems,et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. , 2006, Journal of neurosurgery.
[82] D. Bigner,et al. Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] D L Morton,et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. , 1997, The American journal of pathology.
[84] K. Shin,et al. Superfractionation radiation therapy in the treatment of malignant astrocytoma: Preliminary report , 1980 .
[85] Hermona Soreq,et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.
[86] Y. Yonekawa,et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.
[87] G. Laramore,et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. , 1983, American journal of clinical oncology.
[88] L. Loeb,et al. Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.
[89] D. Xie,et al. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma , 2005, British Journal of Cancer.
[90] W. Brooks,et al. Immune responses in patients with gliomas. , 1974, Surgical neurology.
[91] T. Roszman,et al. Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin‐binding lymphocyte subpopulations in patients with cerebral tumors , 1982, Cancer.
[92] E. Budinská,et al. Screening of genomic imbalances in glioblastoma multiforme using high-resolution comparative genomic hybridization. , 2007, Oncology reports.
[93] P. Wen,et al. Inhibiting kinases in malignant gliomas , 2007, Expert opinion on therapeutic targets.
[94] Parkin Dm,et al. Cancer Incidence in Five Continents. Comparability and quality of data. , 1992 .
[95] E Carrani,et al. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[96] F. Waldman,et al. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization , 1995, International journal of cancer.
[97] Pedro Martínez,et al. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling , 2006, Molecular Cancer.
[98] H. Ohgaki,et al. Genetic pathways to glioblastomas , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.
[99] G. Bonadonna,et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. , 1979, Cancer clinical trials.
[100] Erwin G. Van Meir,et al. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. , 1999, Cancer research.
[101] M. Walker,et al. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.
[102] G. Dohrmann,et al. Glioblastoma multiforme in children. , 1976, Journal of neurosurgery.
[103] K. Kinzler,et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[104] R. McLendon,et al. Tumor antigens in astrocytic gliomas , 1995, Glia.
[105] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[106] M. Feldstein,et al. Introduction--workshop on characterizing the effects of endocrine disruptors on human health at environmental exposure levels , 1999, Environmental health perspectives.
[107] C. James,et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[108] S. Miescher,et al. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. , 1986, Journal of immunology.
[109] C. Heldin,et al. Mechanisms of platelet‐derived growth factor–induced chemotaxis , 2001, International journal of cancer.
[110] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[111] J. Coligan,et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. , 1999, Journal of immunology.
[112] Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. , 2008, International journal of radiation oncology, biology, physics.
[113] S B Green,et al. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] M. J. van den Bent,et al. EORTC Brain Tumor Group: achievements and perspectives. , 2002, European journal of cancer.
[115] A. Friedman,et al. Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas , 2008, Clinical Cancer Research.
[116] D. Louis,et al. Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors , 1993, Journal of neuropathology and experimental neurology.
[117] G. Fuller,et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★ , 2006, Journal of Neuro-Oncology.
[118] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[119] P. Band,et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. , 1976, The New England journal of medicine.
[120] P. Graham. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[121] Ying Mao,et al. CLINICAL EVALUATION AND FOLLOW‐UP OUTCOME OF DIFFUSION TENSOR IMAGING‐BASED FUNCTIONAL NEURONAVIGATION: A PROSPECTIVE, CONTROLLED STUDY IN PATIENTS WITH GLIOMAS INVOLVING PYRAMIDAL TRACTS , 2007, Neurosurgery.
[122] D. Nelson,et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. , 1983, International journal of radiation oncology, biology, physics.
[123] Yiting Cao,et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] S. Green,et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. , 1992, Journal of neurosurgery.
[125] J. Hainfellner,et al. Malignant glioma: Neuropathology and Neurobiology , 2006, Wiener Medizinische Wochenschrift.
[126] T. Roszman,et al. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. , 1980, Clinical and experimental immunology.
[127] P. Gutin,et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.
[128] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[129] S B Green,et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.
[130] P. Demers,et al. Occupation, socioeconomic status, and brain tumor mortality: a death certificate-based case-control study. , 1991, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[131] Robert E. Gentry,et al. Immunobiology of primary intracranial tumors. , 1977, Journal of neurosurgery.
[132] C. Heldin,et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.
[133] J. Lankelma,et al. Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center. , 1981 .
[134] R. Mirimanoff,et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[135] W. Cavenee,et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[136] D. Bigner,et al. Molecular pathogenesis of malignant gliomas. , 1999, Current opinion in oncology.
[137] P. Band,et al. Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas. , 1976, Journal of neurosurgery.
[138] A. Bergenheim,et al. High-grade astrocytoma treated concomitantly with estramustine and radiotherapy , 2006, Journal of Neuro-Oncology.
[139] J. Hoeijmakers. Genome maintenance mechanisms for preventing cancer , 2001, Nature.
[140] W. Lewin,et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. , 1981, British Journal of Cancer.
[141] W. Taylor,et al. Controlled study of CCNU and radiation therapy in malignant astrocytoma. , 1976, Journal of neurosurgery.
[142] D. Áfra,et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas , 1994, Neurology.
[143] P. Steinbok,et al. Superfractionated radiotherapy in grade III, IV intracranial gliomas. , 1988, International journal of radiation oncology, biology, physics.
[144] R. Hellman,et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[145] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[146] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[147] D M Parkin,et al. Cancer Incidence in Five Continents. Comparability and quality of data. , 1992, IARC scientific publications.
[148] B. Scheithauer,et al. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma , 1997, Journal of Neuro-Oncology.
[149] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[150] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[151] K. Hess,et al. Adult glioma incidence trends in the United States, 1977–2000 , 2004, Cancer.
[152] R. Tarnawski,et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. , 2006, Hybridoma.
[153] M. Netsky,et al. DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS , 1972, The Journal of experimental medicine.
[154] H. Eyre,et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery , 2004, Journal of Neuro-Oncology.
[155] K. Sasaki,et al. Investigation of genetic alterations associated with the grade of astrocytic tumor by comparative genomic hybridization , 1998, Genes, chromosomes & cancer.
[156] Jan C Buckner,et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[157] V P Collins,et al. Brain tumours: classification and genes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[158] D. Schoenfeld,et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.
[159] Edward Pan,et al. Glioblastoma Multiforme and Anaplastic Astrocytoma , 2003 .
[160] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[161] D. Bigner,et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. , 1998, Journal of neurovirology.
[162] D. Reardon,et al. Diagnosis and treatment of high-grade astrocytoma. , 2007, Neurologic clinics.
[163] Manfred Westphal,et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.
[164] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[165] T. Roszman,et al. Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. , 1990, The Journal of clinical investigation.
[166] M. Berger,et al. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. , 1998, Cancer research.
[167] R. Hatlevoll,et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.
[168] A. Friedman,et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. , 1991, Journal of neurosurgery.
[169] L. Salford,et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4 , 1991, Cancer.